混合模型框架下的模型，如潛變量增長混合模型（latent growth mixture modeling，LGMM）或潛類別增長分析（latent class growth analysis，LCGA），因估算過程中涉及多個決策過程，導致潛變量軌跡分析結果的報告呈現多樣性。為解決這一問題，指南制訂小組按照系統化的制訂流程，通過 4 輪德爾菲法調查，遵循專家小組意見，提出了各領域報告潛變量軌跡分析結果時需采用統一的標準，最終確定了報告軌跡研究結果必要的關鍵條目，發布了潛變量軌跡研究報告規范（guidelines for reporting on latent trajectory studies，GRoLTS），并利用 GRoLTS 評價了 38 篇使用 LGMM 或 LCGA 研究創傷后應激軌跡的論文的報告情況。
ObjectiveTo systematically review the efficacy of treatments for β-coronaviruses.MethodsPubMed, EMbase, Web of Science, The Cochrane Library, SinoMed, CNKI and WanFang Data databases were electronically searched to collect randomized controlled trials (RCTs) and non-randomized controlled trials (non-RCTs) of treatments for β-coronaviruses from inception to June 17th, 2020. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using Stata 14.0 software.ResultsA total of 109 studies invoving 23 210 patients were included. The results of the systematic review showed that compared with standard of care, corticosteroids could reduce mortality and increase cure rate for COVID-19. However, chloroquine could decrease cure rate. In severe acute respiratory syndrome (SARS) patients, corticosteroids could decrease the cure rate. In Middle East respiratory syndrome (MERS) patients, ribavirin/interferon/both drugs showed higher mortality.ConclusionsThe currently limited evidence shows that corticosteroids may be effective to COVID-19 patients while having limited effects on SARS patients. Hydroxychloroquine or chloroquine may have negative effects on COVID-19 patients. Ribavirin/interferon may be harmful to MERS patients. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusions.